Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emilimogene sigulactibac - Ilya Pharma

Next Previous
Drug Profile

Emilimogene sigulactibac - Ilya Pharma

Alternative Names: ILP-100

Latest Information Update: 31 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ilya Pharma
  • Class Bacteria; Gene therapies; Skin disorder therapies
  • Mechanism of Action Collagen modulators; Immunomodulators; Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic foot ulcer
  • Preclinical Colitis

Most Recent Events

  • 20 Dec 2024 Ilya Pharma terminates phase-II clinical trials in Diabetic-foot-ulcer in Sweden (Topical) due to patient recruitment issues (EudraCT 2021-000563-69) (NCT05608187)
  • 01 Aug 2024 IIya Pharma plans to file IND application with the US FDA in USA for Colitis (IIya Pharma pipeline, August 2024)
  • 01 Aug 2024 IIya Pharma plans a SITU-GUT clinical trial for Colitis (Treatment-naïve) (PO) (IIya Pharmapipeline, August 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top